Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Liver Cancers 1

Interventions

Nivolumab 22Specimen Handling 17pembrolizumab 13cabozantinib 13Magnetic Resonance Spectroscopy 13belzutifan 12Ipilimumab 12lenvatinib 7Axitinib 7CTLA-4 Antigen 6Biopsy 6atezolizumab 4Sunitinib 4tivozanib 3Surveys and Questionnaires 3Immunoglobulin G 3Everolimus 3Disulfides 3relatlimab 2pazopanib 2palbociclib 2aldesleukin 2Watchful Waiting 2Standard of Care 2Radiosurgery 2Practice Guidelines as Topic 2Nephrectomy 2Bevacizumab 2zimberelimab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Tiragolumab × 30 days × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡